Aim We aimed to investigate whether CNF1 plays an active role in CRC onset and progression in vivo. Methods We adapted a well-characterized inflammatory carcinogenesis model (AOM/DSS model). In the first setting, we replaced AOM with monthly intrarectal administrations of CNF1 in mice treated with 2%DSS to evaluate the carcinogenic potential of CNF1. In the second setting, we intrarectally administered CNF1 to AOM/DSS-treated animals to verify the impact of CNF1 on CRC progression. Colonoscopy inspections and histopathological analysis were carried out in both settings to identify CNF1-induced changes in the colonic tissue. Immunohistochemistry and immunofluorescence stainings of colon tissue were also carried out. Results Treatment with CNF1 alone altered the morphological characteristics of the mucosa according to parameters scored at colonoscopy. In addition, CNF1 increased the number of dysplastic aberrant crypt foci (ACF) and enhanced staining for 53BP1, a marker of DNA double-strand breaks. Interestingly, combined treatment with CNF1 and DSS led to the formation of colon adenomas, which were infiltrated by neutrophils. In the AOM/DSS model, addition of CNF1 accelerated tumor development and produced the formation of adenocarcinomas already after two months of treatment. Conclusion In conclusion, our data suggest that CNF1 exerts a pro-tumoral effect on intestinal cells in vivo.
CNF1 from E. coli favors colorectal cancer development and progression / Tozzi, Michela; Fiore, Alessia; Laterza, Ilenia; Rinzo, Paola; Donati, Simona; Travaglione, Sara; Angela Pia Germinario2, Elena; Leoni, Omar; Macchia, Daniele; Spada, Massimo; Tomasoni, Sofia; Verin, Ranieri; Colella, Filomena; Lucchetti, Donatella; Sistigu, Antonella; Maroccia, Zaira; Fabbri And Laura Bracci, Alessia. - (2024). (Intervento presentato al convegno AICC- Associazione Italiana Colture Cellulari tenutosi a Roma).
CNF1 from E. coli favors colorectal cancer development and progression
Michela Tozzi;Alessia Fiore;Ilenia Laterza;Paola Rinzo;Sara Travaglione;
2024
Abstract
Aim We aimed to investigate whether CNF1 plays an active role in CRC onset and progression in vivo. Methods We adapted a well-characterized inflammatory carcinogenesis model (AOM/DSS model). In the first setting, we replaced AOM with monthly intrarectal administrations of CNF1 in mice treated with 2%DSS to evaluate the carcinogenic potential of CNF1. In the second setting, we intrarectally administered CNF1 to AOM/DSS-treated animals to verify the impact of CNF1 on CRC progression. Colonoscopy inspections and histopathological analysis were carried out in both settings to identify CNF1-induced changes in the colonic tissue. Immunohistochemistry and immunofluorescence stainings of colon tissue were also carried out. Results Treatment with CNF1 alone altered the morphological characteristics of the mucosa according to parameters scored at colonoscopy. In addition, CNF1 increased the number of dysplastic aberrant crypt foci (ACF) and enhanced staining for 53BP1, a marker of DNA double-strand breaks. Interestingly, combined treatment with CNF1 and DSS led to the formation of colon adenomas, which were infiltrated by neutrophils. In the AOM/DSS model, addition of CNF1 accelerated tumor development and produced the formation of adenocarcinomas already after two months of treatment. Conclusion In conclusion, our data suggest that CNF1 exerts a pro-tumoral effect on intestinal cells in vivo.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
